ATTENTION AMPH SHAREHOLDERS: Investors who lost money on Amphastar Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Amphastar Pharmaceuticals, Inc. for potential violations of federal securities laws. This follows the FDA's secondary complete response letter regarding Amphastar's generic teriparatide ANDA, AMP-015, after delays in its submission.
February 20, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amphastar Pharmaceuticals is under investigation by Levi & Korsinsky for potential securities law violations after receiving a secondary complete response letter from the FDA for its generic teriparatide ANDA, AMP-015.
The investigation by Levi & Korsinsky into potential securities law violations is likely to negatively impact Amphastar's stock price in the short term. The FDA's secondary complete response letter indicates regulatory challenges, which could further pressure the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100